ReviewJournal of clinical neurology (Seoul, Korea)2019
Therapeutic Interventions in Adult Low-Grade Gliomas.
Review in Journal of clinical neurology (Seoul, Korea), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- TMBIM6 promotes glioma progression according to integrated bioinformatics and experimental evidence.Scientific reports · 2025Article
- Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.International journal of surgery (London, England) · 2025Article
- Utility of Early Postoperative DWI to Assess the Extent of Resection of Adult-Type World Health Organization Grade 2 and 3 Diffuse Gliomas.AJNR. American journal of neuroradiology · 2024Observational
- A 10-Year Survival-Trend Analysis of Low-Grade Glioma and Treatment Patterns from an LMIC.Asian journal of neurosurgery · 2023Article
- The Expression Pattern and Clinical Significance of Lysyl Oxidase Family in Gliomas.Doklady. Biochemistry and biophysics · 2023Article
- Identification of autophagic target RAB13 with small-molecule inhibitor in low-grade glioma via integrated multi-omics approaches coupled with virtual screening of traditional Chinese medicine databases.Cell proliferation · 2021Article
- Oncogene or tumor suppressor? Long noncoding RNAs role in patient's prognosis varies depending on disease type.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Multiomics Profiling and Clustering of Low-Grade Gliomas Based on the Integrated Stress Status.BioMed research international · 2021Article
- RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.BMC bioinformatics · 2019Article
- Application of an Artificial Intelligence Algorithm to Prognostically Stratify Grade II Gliomas.Cancers · 2019Article
- Overexpression ofCancers · 2019Article
- Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating adult low-grade gliomas (LGGs) is particularly challenging due to the highly infiltrative nature of this type of brain cancer. Although surgery, radiotherapy, and chemotherapy are the mainstay treatment modalities for LGGs, the optimal combination management plan for a particular patient based on individual symptoms and the risk of treatment-induced toxicity remains unclear. This review highlights the competency and limitations of standard treatment options while providing an essential therapeutic update regarding current clinical trials aimed at implementing targeted therapies with morbidity rates lower than those for current LGG treatments and also augmenting the killing of cancerous cells while maintaining an improved quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.